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journal homepage: www.elsevier.com/locate/ihjCardiovascular disease (CVD) is the leading cause of death
worldwide. Nearly 80% of the deaths due to CVD occur in low-
income and middle-income countries (LMICs), and 58% of
deaths are in those aged less than 60 years.1,2 There has been a
marked decline in the CVD mortality rates in many developed
nations. Majority of the decline has been attributed to
population level risk factor reduction strategies and individ-
ual-based primary prevention strategies targeted at high-risk
groups to prevent onset of CVD through reduction in the risk
factors like total cholesterol, systolic blood pressure, and
smoking prevalence. The treatment of established CVD,
including secondary preventive therapies, contributed only
to a lesser extent to the decline.2
The concept of medical intervention based on estimated
total CVD risk in the asymptomatic population without CVD is
now widely advocated in many developed nations. Total CVD
risk for an asymptomatic individual is estimated from several
risk factors and is expressed as a probability (percentage
chance) of developing CVD over a deﬁned period of time.3 The
rationale for estimating total CVD risk, based on the major risk
factors, is that the process of atherosclerosis underlying most
of the CVD is usually the result of combined effect of multiple
risk factors rather than a single risk factor. These risk factors
tend to cluster, and also coexistent risk factors tend to have a
multiplicative effect on CVD risk.4 Identiﬁcation of individuals
with high risk can make it easy for physicians to estimate total
CHD risk as a basis for prescribing antiplatelet, antihyperten-
sive, or lipid lowering therapy in the context of CVD prevention
in the asymptomatic population.1 The risk scores can also be
used to estimate and monitor population distribution of CVD
risk from cross-sectional survey of population samples.
National health planners may use population distribution of
total CVD risk to assess total preventive needs and associated
costs, as well as to monitor net effectiveness of interventionsthat affect multiple CVD risk factors by different magnitudes
and direction.2
In this issue of Indian Heart Journal, authors Ofori SN and
Odia OJ have reviewed various risk estimation systems
available for CVD risk stratiﬁcation and discussed the systems
that can be used in LMICs. The ﬁrst risk estimation system was
developed by the Framingham group in 1976. Since then, many
risk estimation systems have been developed. A cardiovascu-
lar risk prediction model will perform well in a given
population if three major characteristics are similar in both
the test population and the population from which the model
was developed. These characteristics are: (1) the nature and
strength of the association between each risk factor included
in the model and the risk of a cardiovascular event; (2) mean
levels (or prevalences) of the risk factors; and (3) background
incidence of CVD.5 The CVD risk stratiﬁcation in low- and
middle-income countries has few limitations.6 The risk
estimation systems should be derived from a study population
with sufﬁcient sample size that is representative of the
population to which the function is to be applied.7 Most of
the available risk prediction systems are derived from
European descent population in high-income countries. Risk
scores based on studies conducted in high-income group
populations may not be suitable for use in low resource
settings.6 But many of the developing countries lack informa-
tion on cardiovascular events that are required for full
calibration of cardiovascular risk prediction models.8 There
are no country speciﬁc cohort studies of CVD risk factors,
morbidity, and mortality in most of the LMICs. Therefore no
validated or calibrated cardiovascular risk prediction charts
have been developed for their populations.1 Hence the World
Health Organization and International Society of Hypertension
(WHO/ISH) have developed sets of regional risk prediction
charts based on fewer risk factors that can be assessed by
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setting for CVD prevention in each of the 14 WHO subregions.
The charts were produced using population-based standard-
ized collection and assessment of data on risk factor
prevalence and relative risk. WHO/ISH charts enable cardio-
vascular risk assessment and prediction in LMICs populations
of all WHO subregions on the basis of age, sex, SBP, type 2
diabetes mellitus, smoking status, and total serum cholester-
ol.9 But in a recent study by Selvarajah et al., the WHO/ISH
model, which was evaluated in the Malaysian population,
incorrectly categorized most people into low cardiovascular
risk group. Hence the performance of risk assessment models
has to be assessed in the population of interest before the risk
assessment models are incorporated into clinical practice.8
The second limitation is that the facilities required to
assess the biochemical parameters (both in terms of human
resources and equipment) for CVD risk stratiﬁcation may not
be available in LMICs. The WHOCVD risk management
package in 2002 considered three different scenarios in
terms of human resources: (1) the nonphysician health
worker, (2) specially trained health nurse or medical doctor,
and (3) medical doctor with access to full medical care.10 The
concept of Multipurpose Health Workers (Male and Female)
(MPHW) was introduced in India in 1974 for the delivery of
preventive and promotive healthcare services to the com-
munity at the level of Sub-Health Centers (SHCs), the most
peripheral health facilities, covering a population of 5000
people in plains and 3000 in hilly/tribal/difﬁcult areas.
Though the main focus of MPHW is mainly on activities
that are related to disease control programs, detection, and
control of epidemic outbreaks, they are also involved in
preventive healthcare. The services of MPHW can be utilized
by providing them proper training in collecting various
parameters in the risk charts. Involving the MPHW will take
care of the human resources problem to a great extent in an
Indian context.11
Many low resource settings, particularly in the LMICs, have
health centers without facilities for cholesterol testing. The
WHO/ISH has developed charts that exclude cholesterol
measurements and can be used in these settings. It has also
been shown that the use of body mass index in place of lipid
measurements results in only slightly inferior discrimina-
tion.8,12 In places where blood glucose estimation is not
possible, it is often feasible to check urine sugar as a surrogate
measure for diabetes. Assessment of proteinuria can also be
included in the risk estimation charts as it is easy to measure,
though the CVD risk may be higher than indicated in the chart
in people with proteinuria.8 The cost of uristix, which
measures both urine sugar and protein, is only 20% of the
cost of blood glucose measuring strips by glucometer and costs
much less than blood glucose measurement by reagents in the
lab. It does not require pricking the body, and thus avoids pain,
which may be a deterrent for testing in general population.
However, urine testing has few limitations in that it provides a
measurement of glucose levels since the person last passed
urine and does not reﬂect the current blood glucose level. Also
the results do not differentiate between slightly and markedly
raised blood glucose levels. If the urine is free of glucose, it
does not necessarily mean that the blood glucose level is
normal, as the appearance of glucose in the urine depends onthe renal threshold for glucose, especially in the elderly
people, where the threshold may be higher.13
Measurement and monitoring of population level total CVD
risk may provide important guidance to health planners to
monitor trends and impact of multifactorial interventions.14
At an individual level, the total risk approach can help
clinicians to ensure that individuals who are at greatest risk
receive treatment, which is a more cost-effective approach
than treatment based on single, elevated risk factor approach
and overall, low total CVD risk.3 Unfortunately, there is a lot of
underutilization of CVD prevention guidelines in clinical
practice. Even in the developed countries where the guidelines
advocating use of total risk scores are available, their adoption
has been slow. Steps should be taken to improve the utilization
of available scores. Most of the LMICs are yet to issue any
guidelines for screening and management of risk factors based
on total CVD risk assessment approach. Hence, it may be of
value to intensively pilot the implementation of WHO guide-
lines using WHO/ISH risk prediction charts. It will help to
understand the various operational issues. The validation of
charts should be completed before advocating large-scale use.2
Lastly, more research is required to quantify clinical beneﬁt
and cost effectiveness of the total risk assessment approach.
Clinicians are more likely to adopt the new approach if there is
evidence of better clinical outcomes and cost effectiveness.2,7
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